Fei-Fei Han1, Lu-Lu Ren2, Ling-Ling Xuan2, Ya-Li Lv2, He Liu2, Li-Li Gong2, Zhuo-Ling An2, Li-Hong Liu3. 1. Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China. Hanfeifei@163.com. 2. Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China. 3. Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China. Liulihong@bjcyh.com.
Abstract
OBJECTIVE: Rate-limiting enzyme 3b-hydroxysteroid dehydrogenase type 1 (3βHSD1) encoded by HSD3B1 catalyzes the transition of dehydroepiandrosterone (DHEA) to dihydrotestosterone (DHT). The HSD3B1 (1245C) variant renders 3bHSD1 of resistant to ubiquitination and degradation, leading to a large amount of protein accumulation in the cell. Multiple clinical studies have shown that this mutation was correlated with resistance to androgen-deprivation therapy in prostate cancer. However, the results were not consistent depending on different treatment strategy and in some researches, the number of observed cases was relatively small. METHODS: To determine the effects of HSD3B1 (1245C) variant on resistance to androgen-deprivation therapy in prostate cancer, we performed a meta-analysis of the available literature. Electronic database searches identified appropriately designed studies that detected HSD3B1 in prostate cancer. We conducted a systematic search of studies in the following databases: PubMed, and EMBASE published until August 10, 2020 using the following search terms: (HSD3B1 AND ((((prostate cancer) OR prostatic neoplasm) OR prostatic carcinoma) OR prostatic cancer). RESULTS: Eight researches were included in this research. The result validated that the HSD3B1 (1245C) variant allele was associated with a shorter PFS (HR, 1.97; 95% CI, 1.39-2.79; P = 0.0001) (homozygous wild-type group) in men with prostate cancer when treated with ADT, however, a higher PFS (HR, 0.68; 95% CI, 0.48-0.96; P = 0.03) when treated with ADT and CYP17A1 inhibitor. CONCLUSION: The HSD3B1 (1245C) variant is a predictor of ADT plus CYP17A1 inhibitor response in prostate cancer.
OBJECTIVE: Rate-limiting enzyme 3b-hydroxysteroid dehydrogenase type 1 (3βHSD1) encoded by HSD3B1 catalyzes the transition of dehydroepiandrosterone (DHEA) to dihydrotestosterone (DHT). The HSD3B1 (1245C) variant renders 3bHSD1 of resistant to ubiquitination and degradation, leading to a large amount of protein accumulation in the cell. Multiple clinical studies have shown that this mutation was correlated with resistance to androgen-deprivation therapy in prostate cancer. However, the results were not consistent depending on different treatment strategy and in some researches, the number of observed cases was relatively small. METHODS: To determine the effects of HSD3B1 (1245C) variant on resistance to androgen-deprivation therapy in prostate cancer, we performed a meta-analysis of the available literature. Electronic database searches identified appropriately designed studies that detected HSD3B1 in prostate cancer. We conducted a systematic search of studies in the following databases: PubMed, and EMBASE published until August 10, 2020 using the following search terms: (HSD3B1 AND ((((prostate cancer) OR prostatic neoplasm) OR prostatic carcinoma) OR prostatic cancer). RESULTS: Eight researches were included in this research. The result validated that the HSD3B1 (1245C) variant allele was associated with a shorter PFS (HR, 1.97; 95% CI, 1.39-2.79; P = 0.0001) (homozygous wild-type group) in men with prostate cancer when treated with ADT, however, a higher PFS (HR, 0.68; 95% CI, 0.48-0.96; P = 0.03) when treated with ADT and CYP17A1 inhibitor. CONCLUSION: The HSD3B1 (1245C) variant is a predictor of ADT plus CYP17A1 inhibitor response in prostate cancer.
Entities:
Keywords:
Androgen-deprivation therapy; Gene variation; HSD3B1; Prostate cancer
Authors: Neeraj Agarwal; Andrew W Hahn; David M Gill; James M Farnham; Austin I Poole; Lisa Cannon-Albright Journal: JAMA Oncol Date: 2017-06-01 Impact factor: 31.777
Authors: Jason W D Hearn; Ghada AbuAli; Chad A Reichard; Chandana A Reddy; Cristina Magi-Galluzzi; Kai-Hsiung Chang; Rachel Carlson; Laureano Rangel; Kevin Reagan; Brian J Davis; R Jeffrey Karnes; Manish Kohli; Donald Tindall; Eric A Klein; Nima Sharifi Journal: Lancet Oncol Date: 2016-08-27 Impact factor: 41.316
Authors: Jason W D Hearn; Wanling Xie; Mari Nakabayashi; Nima Almassi; Chad A Reichard; Mark Pomerantz; Philip W Kantoff; Nima Sharifi Journal: JAMA Oncol Date: 2018-04-01 Impact factor: 31.777
Authors: Zhenfei Li; Mohammad Alyamani; Jianneng Li; Kevin Rogacki; Mohamed Abazeed; Sunil K Upadhyay; Steven P Balk; Mary-Ellen Taplin; Richard J Auchus; Nima Sharifi Journal: Nature Date: 2016-05-26 Impact factor: 49.962